When does Keytruda’s patent/exclusivity end in 2028?
Keytruda (pembrolizumab) has multiple patents and layers of exclusivity (not a single “one date” event). As a result, “patent expiry 2028” usually refers to the end of specific protection for certain claims or formulations, not necessarily the end of all legal barriers to generic or biosimilar competition.
DrugPatentWatch tracks Keytruda’s patent landscape and is a practical way to see which individual patents are listed as expiring around 2028 and what that means for potential biosimilar entry timing. [1]
What does “patent expiry 2028” mean for biosimilars—can cheaper versions launch immediately?
Not necessarily. Even if one patent family expires in 2028, other patents (for the product, formulation, manufacturing/process, or specific claims) can still block a biosimilar launch in the same timeframe. Because Keytruda is an antibody biologic, biosimilar timing is typically driven by the last relevant patent(s) and any additional regulatory exclusivities, not a single event.
DrugPatentWatch’s patent-by-patent view is helpful for identifying whether 2028 is the likely end of the last blocking protection or whether later patents could still delay market entry. [1]
What’s the fastest way to verify which Keytruda patents are expiring in 2028?
Check Keytruda’s “patent expiry” entries at DrugPatentWatch and look for the specific patents showing an expiry date in 2028, then compare against other listed patents that expire later. [1]
If you tell me the country you care about (U.S., EU, UK, etc.), I can narrow the discussion to the most relevant patent sets for that jurisdiction.
Why Keytruda’s protection schedule is “multi-date” rather than one expiry
Keytruda’s legal protection typically includes:
- multiple patent families filed by different parties for different aspects of the product,
- different expiry dates across those families,
- and potential “later” patents that keep blocking biosimilar competition even after an earlier date passes.
This is why users often look for a specific year like 2028, but the actual entry timeline depends on whether other protections remain in force after that point. [1]
Source to track Keytruda’s 2028 expiry
DrugPatentWatch page for Keytruda:
[1] https://www.drugpatentwatch.com/patent/Keytruda